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ABSTRACT
When an infected patient suffers from thrombocytosis, it is very difficult to identify beta-lactam antibiotic-induced cases of the disease and separate 
those from the possibility that thrombocytosis is an acute-phase reaction in the infected patient. We present 3 cases who were treated with Augmentin 
for various indications and developed thrombocytosis during the treatment course. The Naranjo probability scale indicates Augmentin as the possible 
cause of the thrombocytosis in all our patients.
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INTRODUCTION
It is very difficult to identify antibiotic-induced thrombocytosis in an 
infected patient since infection by itself one of the commonest causes 
of reactive thrombocytosis. Many drugs are implicated in causing 
reactive thrombocytosis with Adrenaline being the first one discovered 
to cause reactive thrombocytosis. Other agents include vinca alkaloids, 
miconazole, and iron preparations. Hence, we present 3 patients 
(case series) treated with Augmentin for various indications and 
developed thrombocytosis during the treatment course.
CASE REPORTS
Case 1
Informed consent was taken from the patient. A 50-year-old female 
patient diagnosed of ovarian carcinoma underwent cytoreduction 
surgery. Post-surgery patient was started on meropenem on September 
18, 2016, and later with Augmentin on September 23, 2016. 5 days after 
starting with Augmentin patient developed elevated platelet counts and 
counts kept on increasing. On October 4, 2016, platelet counts were high 
and Augmentin was suspected to be causative agent. All other causes 
were ruled, and Augmentin was stopped. Intravenous fluid correction 
was given and she recovered on October 11, 2016 with platelet counts 
returning to normal levels (Table 1).
Case 2
Informed consent was taken from patient. A 75-year-old patient 
diagnosed of malignant melanoma of the right 4th toe underwent 
surgical excision along with right groin lymph node dissection on June 
21, 2016. The patient was started on Augmentin on June 21, 2016, and 
she developed elevated platelet counts on July 4, 2016 and platelet 
counts continue to elevate till July 9, 2016. Augmentin was stopped on 
July 5, 2016, and intravenous fluid correction was given (Table 2). The 
patient slowly recovered back.
Case 3
Informed consent was taken from the patient. We report a 65-year-old 
female patient, known case of metastatic adenocarcinoma rectum with 
bladder infiltration, Stage IV CT4BN2M1B, admitted to the Oncology 
Department of our hospital with complaints of severe diarrhea for 
20 days. Her history revealed that she was an old case of carcinoma 
endometrium diagnosed in 1999. A complete physical examination 
revealed pallor and enlarged right inguinal lymph nodes. Per rectal 
examination revealed an anal growth of 5 cm from the anal verge. 
Her laboratory parameters revealed mild anemia with leukocytosis. 
In view of the above signs and symptoms, patient was taken up for 
cystoscopy and sigmoidoscopy under the cover of a broad spectrum 
antibiotic Augmentin (amoxicillin with clavulanic acid) 1 g on July 
16th 2016. Following the second dose of Augmentin, her laboratory 
parameters revealed thrombocytosis with a platelet count of about 
4,54,000, and the counts kept on increasing to 5,59,000 after 1 week 
of Augmentin therapy as on 21st of July 2016 (Table 3). Others causes 
of thrombocytosis were ruled out, and Augmentin was stopped on 21st, 
and patient platelet counts came down to normal levels.
DISCUSSION
Thrombocytosis is generally defined as platelets counts above 4,00,000. 
Patients with systemic inflammation, tumors, bleeding, drugs, trauma, 
stress, iron deficiency anemia may have elevated platelet counts, a 
condition called secondary or reactive thrombocytosis.
Antibiotic-induced reactive thrombocytosis is relatively 
uncommon and extreme thrombocytosis is very rare. There are 
three major categories of thrombocytosis, namely, secondary or 
reactive thrombocytosis, hereditary thrombocythemia, and clonal 
thrombocytosis, including essential thrombocythemia and related 
myeloproliferative disorders. Many classes of drugs are implicated 
in causing reactive thrombocytosis such as vinca alkaloids, iron 
preparations, and also beta-lactam antibiotics. However, antibiotic-
induced cases of thrombocytosis are very difficult to interpret due to 
the possibility of an acute-phase reaction in an infected patient being 
the actual cause of the thrombocytosis [1].
Amoxicillin originally introduced in the early 1970’s for oral use in 
the United Kingdom was later used in different formulations and 
combinations to treat various diseases [2]. Amoxicillin/clavulanic 
acid (Augmentin), is an established combination of a semisynthetic 
antibacterial agent, amoxicillin and a beta-lactamase inhibitor, 
clavulanic acid. Penicillin-susceptible strains of Streptococcus 
pneumonia and beta-lactamase producing strains of Haemophilus 
influenza and Moraxella catarrhalis are highly susceptible to Augmentin 
and penicillin-resistant strains are moderately susceptible to this 
drug combination. Amoxicillin/clavulanic acid causes many adverse 
reactions. It includes skin reactions (78%), gastrointestinal (13%), 
hepatic (4%), hematological toxicity (2%) [3]. There are few case 
reports of reactive thrombocytosis with beta-lactam and beta-lactamase 
inhibitor combination [4-6]. Augmentin-induced thrombocytosis 
is extremely rare with so far only one case report reported as per 
literature [7].
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In our patient’s thrombocytosis developed after starting Augmentin 
and all patients recovered back to normal after discontinuing the 
drug. Rechallenge was not done, and other possible causes of reactive 
thrombocytosis such as infections, Kawasaki disease, inflammatory 
bowel disease, hemolytic anemias, connective tissue disorders, other 
drugs such as vinca alkaloids, steroids, antifungals, haloperidol, 
and iron preparations were ruled out. Mechanisms underlying 
Augmentin-induced thrombocytosis is not clear yet as per literature 
evidence, possibility of bone marrow response to thrombopoietin 
leading to elevated platelet counts is worth a mention here [8].
Causality assessment was done as per Naranjo’s scale [9], and a probable 
causal relationship was established (Table 4). It was also found that the 
adverse drug reaction was of mild severity and was not preventable as 
per Hartwig’s and Thornton’s scale, respectively [9].
CONCLUSION
Although no obvious complications occurred in most patients, we 
should pay close attention to the possibility of adverse reactions. 
Reactive thrombocytosis due to Augmentin should be kept in mind, 
and it is prudent enough to rule out other causes of secondary 
thrombocytosis as infection can result in elevated platelet counts. 
Further prospective studies can be done to find out the incidence of 
thrombocytosis associated with combination of beta-lactam antibiotics 
and beta-lactamase inhibitors.
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Table 1: Case 1 ‑ Platelet counts after Augmentin therapy
Date Platelet counts
September 23, 2016 310×103/UL
September 29, 2016 480×103/UL
October 04, 2016 785×103/UL
October 11, 2016 310×103/UL
Table 2: Case 2 ‑ Platelet count after Augmentin therapy
Date Platelet counts
July 01, 2016 288×103/UL
July 04, 2016 408×103/UL
July 09, 2016 785×103/UL
Table 3: Case 3 ‑ Platelet count after Augmentin therapy
Date Platelet counts
July 13, 2016 344×103/UL
July 17, 2016 444×103/UL
July 21, 2016 559×103/UL
Table 4: Adverse drug reaction assessment
Naranjo’s scale Hartwig’s scale Thornton’s scale
Probable Mild severity Not preventable
